Vision & Mission

Methodology

Leadership

Action Team

Our Vision

SCAN-2030 aims to establish a HTA ecosystem in Hong Kong, enhancing the access, delivery, and introduction of innovative and cost-effective medications. By implementing an evidence-based evaluation system, we provide a pipeline of global medicines (Horizon Scanning) and develop prioritization criteria (HTA) to ensure healthcare system preparedness.

Our Mission

We utilise Hong Kong's population-based electronic medical records to understand disease burden and unmet needs, as well as to project future healthcare requirements. We develop decision assistance toolkits to assess the 10-year disease burden, cost-effectiveness, return on investment, and budget impact of innovative medicines for Noncommunicable diseases (NCDs). Our mission is achieved through three interconnected work packages:

Understanding Disease Burden, Patient Journeys and Unmet Needs

Projecting 10-year Population-specific Disease and Economic Burden

Evaluating the Value-for-money of Innovative Medicines

Project Roadmap

The project will benefit different stakeholders in the short (1-3 years), medium (4-10 years) and long term (over 10 years).

Short-term Benefits
(Year 1-3)

Medium-term Benefits
(Year 4-10)

Long-term Benefits
(over 10 years)

Short-term Benefits (Year 1-3)

Reveal the recent 10-year disease burden and nowcast the unmet needs for the next ten years

Locate the service gaps and boost the public formulary listing for innovative medicines

Benefit the three target therapeutic areas (mental illness, autoimmune diseases, and cancer) with early innovative medicine access

Achieve improved survival and quality of life

Medium-term Benefits (Year 4-10)

Establish a dynamic web portal visualizing the local unmet needs with monitoring of innovative medicines in the global R&D pipeline in 4-10 years

Benefit policymakers and industry stakeholders

Strengthen the understanding of the disease and economic burden, the budget required for innovative medicine introduction and the local market size for facilitating stakeholders in making the best decision for the public or their companies

Long-term Benefits (over 10 years)

Facilitate the establishment of an HTA center with a focus on economic evaluation in Hong Kong

Pass the methodological expertise onto researchers and stakeholders to learn and interpret modelling economic evaluation

Enhance transparency of the formulary listing process, which incentivises the R&D, marketing and access planning from the supply side

Overcome the problem of overburdened public health system in Hong Kong with aging population